



RECEIVED
TECH CENTER
SEP 2 2003




FIGURE 2


U.S. PATENT & TRADEMARK OFFICE
SEP 17 2003
RECEIVED

3/20

RECEIVED
SEP 12 2003
TECH CENTER 1600/2900

3B


3A



COPIE JC 2
SEP 17 2003
PATENT & TRADEMARK OFFICE

4 / 20

SFV-prME




SFV1




A

RECEIVED
SEP 12 2003
TECH CENTER 1600/2900



B



C



Fig. 4.

O P E J C 42131
SEP 17 2003
PATENT & TRADEMARK OFFICE


5/20

RECEIVED
SEP 23 2003
TECH CENTER 1600/2900

A



B



C


Fig. 5.

U.S. PATENT & TRADEMARK OFFICE
SEP 17 2003
RECEIVED

6 / 20


RECEIVED
SEP 22 2003
TECH CENTER 1600/2900

A



1 2

1 2 3



KUN probe

SFV probe

B

C


Fig. 6

U.S. PATENT & TRADEMARK OFFICE
CIP E
SEP 17 2003
2003
RECEIVED
TECH CENTER 1600/2900

7 / 20


A

Time between
transfections (h) 12 18 24 30



B

Time after 2nd
transfection (h) 24 30 42



Titer, $\times 10^6$
(IU/ 2×10^6 cells) 0.27 3.8 1.3


FIGURE 7

U.S. PATENT & TRADEMARK OFFICE
CPE
SEP 17 2003
342

8/20

RECEIVED
SEP 22 2003
TECH CENTER 1600/2900


B



A



1 2 3



C

F III, 8


D

U.S. PATENT & TRADEMARK OFFICE
C I P E
SEP 17 2003
RECEIVED
PATENT & TRADEMARK OFFICE

9/20

RECEIVED
SEP 22 2003
TECH CENTER 1600/2900

9A



9B

KUN virions



Replicon Particles





FIG. 9

10 A

C20DX2Arep(Neo)

FMDV-2A cleavage



10 B

- C20DX/hcv-trCore/2Arep
- C20DX/hcv-flCore/2Arep
- C20DX/CAT/2Arep
- C20DX/GFP/2Arep
- C20DX/hcv-NS3/2Arep
- C20DX/VSV-G/2Arep
- C20DX/β-GAL/2Arep

10 C


C20DXIRESrep

- hev-trCore (160aa)
- hev-flCore (191aa)
- CAT (218aa)
- GFP (237aa)
- hev-NS3 (436aa)
- VSV-G (509aa)
- β-GAL (1017aa)

10 / 20

RECEIVED
SEP 22 2003
TECH CENTER 1600/2900

Fm 10



O I P E
SEP 17 2003
PATENT & TRADEMARK OFFICE
C 22

11/20

RECEIVED
SEP 9 2 2003

TECH CENTER 1600/2900





Fig 11

10
OCTOBER
2003
12
PATENT & TRADEMARK OFFICE
RECEIVED
SEP 17 2003
12/20

RECEIVED
SEP 9 2003

TECH CENTER 1600/2900

B



A

12
11




Fig. 13 a.

U. S. PATENT & TRADEMARK OFFICE
SEP 17 2003
542

14/20

RECEIVED
SEP 9 2 2003
TECH CENTER 1600/295





Fig. 13 b.



15 / 20

RECEIVED
SEP 22 2003
TECH CENTER 1600/2300



14 B CAT assay




Fig 14

SEP 17 2003
PATENT & TRADEMARK OFFICE
U.S. GOVERNMENT

16 / 20


RECEIVED
SEP 22 2003
TECH CENTER 1600/2900

15A GFP fluorescence



repGFP-BHK (p5)


15 B CAT assay



p6 p17
repCAT-BHK

— Flu 15


A C20DXUb2Arep



17/20

B

anti-NS3 IF



C20DXrep

F_{III} 16

C20DXUb2Arep

RECEIVED
SEP 22 2003
TECH CENTER 1600/2900
PATENT & TRADEMARK OFFICE
C 14 E
SEP 17 2003
CJC
U.S. PATENT & TRADEMARK OFFICE




18 / 20

RECEIVED


SEP 22 2003
TECH CENTER 1600/2330

A C20DXUb2A_HDVrep



B

anti-NS3 IF



C20DXUb2A_HDVrep

C20DXUb2Arep

Fig 17


17 SEP 2003
PATENT & TRADEMARK OFFICE

19 / 20

RECEIVED
17 SEP 2003

TECH CENTER 1600
17 SEP 2003

A pkUNrep1



B anti-NS3 IF



18



RECEIVED
SEP 17 2003
TECH CENTER 1600
U.S. PATENT & TRADEMARK OFFICE

10-11